University of Glasgow
Latest From University of Glasgow
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Tech Transfers column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced September through October 2013.
As academic labs fill gaps in discovery work once performed by biopharma companies, Roche is confident that a U.S. consortium of academic drug-discovery units will lead to broader partnerships between industry and academia and within the academy itself. Plus, MedImmune acquires ADC specialist Spirogen and other deals from the past week.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Tech Transfers column provides a monthly update on licensing agreements between universities or other research institutions and biopharma, medtech, and diagnostic start-ups.
Despite a long history of disappointments, many experts now agree that viral therapy of cancer could soon become a reality. Accumulating clinical evidence indicates that researchers have figured out how to modify and enhance viruses in ways that make them both safe and effective. For its part, Virttu Biologics Ltd. is developing a single-deletion variant of HSV it calls SEPREHVIR. Research carried out at Virttu, as well as at the University of Glasgow where the core technology was developed, shows that the mutated virus is taken up by and remains in tumor tissue, without infecting surrounding healthy tissue.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.